Trending...
- Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI - 118
- Fact check: Claims swirling on California gas prices - 109
- Google AI Quietly Corrects the Record on Republic of Aquitaine's Legal Sovereignty
OXFORD, England and CHICAGO, May 16, 2025 ~ Brainomix, a leading company in AI-powered imaging solutions for lung fibrosis and stroke, will be presenting new evidence at the upcoming American Thoracic Society (ATS) Conference in San Francisco. The evidence will validate the effectiveness of their Brainomix 360 e-Lung technology in accurately and sensitively identifying progressive pulmonary fibrosis.
The validation comes as a result of a research collaboration between Brainomix and Boehringer Ingelheim, a global leader in pulmonary fibrosis therapies. Through this collaboration, Brainomix was granted access to the landmark INBUILD clinical trial dataset to conduct the first quantitative CT analysis. The results have firmly established e-Lung as a reliable tool for identifying progressive pulmonary fibrosis and its prognostic accuracy in predicting patients at risk.
Dr Susanne Stowasser, Associate Head of Medicine Therapeutic Area Inflammation at Boehringer Ingelheim, expressed their commitment to creating value for patients through collaborations. She stated that the imaging data presented at ATS from their INBUILD clinical trial is part of their collaboration with Brainomix and others to advance the development of imaging biomarkers for better prognostication and prediction of response to therapy.
More on The Californer
The studies will be presented on May 21st at ATS by Prof Anand Devaraj and Dr Peter George from the Royal Brompton Hospital in London. They will showcase Brainomix 360 e-Lung, an imaging software powered by novel proprietary technology that automatically quantifies CT biomarkers in patients with interstitial lung disease (ILD). With its recent expansion of FDA clearance, the next generation e-Lung technology represents a significant step forward in improving care for ILD patients with improved AI and machine learning algorithms.
Pulmonary fibrosis is a chronic lung condition that is progressive and life-limiting. Without treatment, patients can have a lifespan as short as three to five years from diagnosis. However, due to challenges in identifying the disease, patients often wait up to two years for a diagnosis. Early initiation of treatment is crucial for the best outcome and survival, but identifying eligible patients based on imaging can be difficult, even for experts.
Dr Peter George, Consultant Pulmonologist at the Royal Brompton NHS Trust UK and Brainomix Medical Director, emphasized the power of e-Lung in accurately identifying progression and its prognostic capabilities. He stated that this ability to track results across multiple scan timepoints can help physicians make better treatment decisions earlier on. The prognostic capabilities also allow physicians to prioritize at-risk patients for earlier follow-up and escalate their care in a timely manner.
More on The Californer
The strategic partnership between Brainomix and Boehringer Ingelheim, announced in 2024, aims to improve the care of patients with progressive pulmonary fibrosis. Early collaborations with leading US pulmonary sites and registries have already provided real-world validation of e-Lung in improving the identification of patients with progressive pulmonary fibrosis.
Brainomix will be exhibiting at ATS (booth #1563) and will have a series of key scientific sessions. The "Imaging-Based Advances in Fibrotic ILD" symposium will take place on Wednesday, May 21 from 11am – 1pm in Rooms 3014-3018, West Building of the Moscone Center. Three (3) Brainomix studies will be presented by Dr Peter George and Prof Anand Devaraj:
- e-Lung Biomarkers Are Associated With Future Progressive Pulmonary Fibrosis Independent of UIP Status on CT
- Baseline Quantitative CT Predicts Rate of Decline in Forced Vital Capacity and Clinically Relevant Outcomes in Patients With Progressive Pulmonary Fibrosis: Results From the INBUILD Trial
- Effect of Nintedanib on Quantitative CT in Patients With Progressive Pulmonary Fibrosis: Results From the INBUILD Trial
In conclusion, Brainomix's innovative e-Lung technology, validated by their collaboration with Boehringer Ingelheim, has the potential to significantly improve the care and outcomes of patients with progressive pulmonary fibrosis. Their studies and presentations at ATS will provide valuable insights and advancements in the field of ILD imaging.
The validation comes as a result of a research collaboration between Brainomix and Boehringer Ingelheim, a global leader in pulmonary fibrosis therapies. Through this collaboration, Brainomix was granted access to the landmark INBUILD clinical trial dataset to conduct the first quantitative CT analysis. The results have firmly established e-Lung as a reliable tool for identifying progressive pulmonary fibrosis and its prognostic accuracy in predicting patients at risk.
Dr Susanne Stowasser, Associate Head of Medicine Therapeutic Area Inflammation at Boehringer Ingelheim, expressed their commitment to creating value for patients through collaborations. She stated that the imaging data presented at ATS from their INBUILD clinical trial is part of their collaboration with Brainomix and others to advance the development of imaging biomarkers for better prognostication and prediction of response to therapy.
More on The Californer
- Independent Financial Group Expands East Coast Recruiting Reach with the Hiring of Former Osaic Executive Bruce Levitus
- Talbot Law Group, P.C. Announces Super Lawyers® 2025 Honors for Matthew B. Talbot and Mark E. Miyasaki
- Bio-Inspired Technology-Dynamic and Adaptable for unknown real-world environments
- California: Governor Newsom challenges President Trump to adopt model executive order to help 'Make America Rake Again'
- Long Beach Airport Named Number Two Airport in Nation by The Washington Post
The studies will be presented on May 21st at ATS by Prof Anand Devaraj and Dr Peter George from the Royal Brompton Hospital in London. They will showcase Brainomix 360 e-Lung, an imaging software powered by novel proprietary technology that automatically quantifies CT biomarkers in patients with interstitial lung disease (ILD). With its recent expansion of FDA clearance, the next generation e-Lung technology represents a significant step forward in improving care for ILD patients with improved AI and machine learning algorithms.
Pulmonary fibrosis is a chronic lung condition that is progressive and life-limiting. Without treatment, patients can have a lifespan as short as three to five years from diagnosis. However, due to challenges in identifying the disease, patients often wait up to two years for a diagnosis. Early initiation of treatment is crucial for the best outcome and survival, but identifying eligible patients based on imaging can be difficult, even for experts.
Dr Peter George, Consultant Pulmonologist at the Royal Brompton NHS Trust UK and Brainomix Medical Director, emphasized the power of e-Lung in accurately identifying progression and its prognostic capabilities. He stated that this ability to track results across multiple scan timepoints can help physicians make better treatment decisions earlier on. The prognostic capabilities also allow physicians to prioritize at-risk patients for earlier follow-up and escalate their care in a timely manner.
More on The Californer
- Dedeaux Properties Begins Construction on Truck Terminal and Industrial Outdoor Storage Facility
- Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
- Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
- Live Courageously Hosts Ann-Marie Murrell, Author, Journalist, Former Political Commentator
- COSRX x Alfred Coffee Launch Skincare-Coffee Crossover
The strategic partnership between Brainomix and Boehringer Ingelheim, announced in 2024, aims to improve the care of patients with progressive pulmonary fibrosis. Early collaborations with leading US pulmonary sites and registries have already provided real-world validation of e-Lung in improving the identification of patients with progressive pulmonary fibrosis.
Brainomix will be exhibiting at ATS (booth #1563) and will have a series of key scientific sessions. The "Imaging-Based Advances in Fibrotic ILD" symposium will take place on Wednesday, May 21 from 11am – 1pm in Rooms 3014-3018, West Building of the Moscone Center. Three (3) Brainomix studies will be presented by Dr Peter George and Prof Anand Devaraj:
- e-Lung Biomarkers Are Associated With Future Progressive Pulmonary Fibrosis Independent of UIP Status on CT
- Baseline Quantitative CT Predicts Rate of Decline in Forced Vital Capacity and Clinically Relevant Outcomes in Patients With Progressive Pulmonary Fibrosis: Results From the INBUILD Trial
- Effect of Nintedanib on Quantitative CT in Patients With Progressive Pulmonary Fibrosis: Results From the INBUILD Trial
In conclusion, Brainomix's innovative e-Lung technology, validated by their collaboration with Boehringer Ingelheim, has the potential to significantly improve the care and outcomes of patients with progressive pulmonary fibrosis. Their studies and presentations at ATS will provide valuable insights and advancements in the field of ILD imaging.
Filed Under: Business
0 Comments
Latest on The Californer
- California: Governor Newsom proclaims Immigrant Heritage Month 2025
- California: Department of Defense agrees: it's time for Trump's militarization of Los Angeles to end
- Long Beach: City Launches Internet Service Enrollment Line
- Von Rock Law Founder Deidre Von Rock Named Super Lawyer for 2025
- California: Governor Newsom extends emergency short-term housing protections in Los Angeles
- Von Rock Law Named SFGate's Best Probate and Estate Attorney in 2025
- Long Beach to Conduct Annual Summer Recess for City Council Meetings During July
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
- Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
- Montessori Stoppani Partners with Lifetime Montessori School
- Cymbiotika Celebrates 2025 Great Place To Work Certification™
- Long Beach: LA28 Announces Finalized Sailing Venue Plan for 2028 Olympic Games
- Individual Software Announces New Versions of its Four Typing Programs in 2025
- Britt Michaelian Brings Transformative Art & Wellness to The Ecology Center's Peace Dome
- California: Governor Newsom urges safety this Fourth of July after 600,000 pounds of illegal explosives seized
- AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
- The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
- Mental and Emotional Self-Management, Practical Tools for Trauma-Informed Stress Management
- CGI+ Sells Multifamily Development Site in Los Angeles' South Bay to JPI for $40 Million
- MicroStrategy Incorporated (MSTR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit